Cancer
3,930
624
806
2,017
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Published Results
417 trials with published results (11%)
Research Maturity
2017 completed trials (51% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.7%
304 terminated out of 3930 trials
86.9%
+0.4% vs benchmark
6%
239 trials in Phase 3/4
21%
417 of 2017 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2017 completed trials
Clinical Trials (3930)
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults With Cancer
Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE)
Chinese American Cancer Survivors Writing Study
Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors
Occupational Cancer Screening in Firefighters: A Pilot Study Within the Inova Health System
Statins to Prevent Cancer Associated Blood Clots
Toxicity of Treatments for Non-tuberculous Mycobacterial Infections in Cancer Patients or Not
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Effects of a Lay-led Anxiety and Depression Self-management Program for Cancer Patients
Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors
BfedBwell Optimization Pilot
Effects of Dietary Supplementation With omega3-fatty Acids (Fish Oil) and Progressive Resistance Training on Skeletal Muscle Status in Gynaecological, Gastrointestinal and Urological Cancer Patients
Dyadic Life Review Intervention for Older Patients With Advanced Cancer) and Their Caregivers
Study of the Effect of Innate on the Inflammatory Response to Endotoxin
CANnabinoids in Pediatric ONCology
EXCEL-Punjabi: A Culturally Tailored Exercise Oncology Pilot Feasibility Intervention
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Connect for Cancer Prevention Study (Connect)